Drug Profile


Alternative Names: MRX I

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MicuRx Pharmaceuticals
  • Class Antibacterials; Oxazolidinones; Skin disorder therapies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • No development reported Methicillin-resistant Staphylococcus aureus infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Skin-and-soft-tissue-infections(In volunteers) in Australia (PO, Tablet)
  • 21 Oct 2016 Phase-III clinical trials in Skin and soft tissue infections in China (PO)
  • 26 Sep 2016 MicuRx Pharmaceuticals plans to file a Chinese NDA for acute bacterial skin and skin structure infections in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top